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Abstract
Conventional chemotherapy-based drug combinations have, until recently, been the backbone of most therapeutic
strategies for cancer. In a time of emerging rationale drug development, targeted therapies are beginning to be added
to traditional chemotherapeutics to synergistically enhance clinical responses. Of note, the importance of pro-
apoptotic ceramide in mediating the anti-cancer effects of these therapies is becoming more apparent. Furthermore,
reduced cellular ceramide in favour of pro-survival sphingolipids correlates with tumorigenesis and most importantly,
drug resistance. Thus, agents that manipulate sphingolipid metabolism have been explored as potential anti-cancer
agents and have recently demonstrated exciting potential to augment the efficacy of anti-cancer therapeutics. This
review examines the biology underpinning these observations and the potential use of sphingolipid manipulating
agents in the context of existing and emerging therapies for haematological malignancies.
Facts
• Efficacy of many chemotherapeutics and targeted therapies is dictated by cellular ceramide levels.
• Oncogene activation skews sphingolipid metabolism to favour the production of pro-survival sphingolipids.
• Inhibitors of enzymes involved in ceramide metabolism exhibit promise in the relapsed-refractory setting.
• Anti-cancer activity of sphingosine kinase inhibitors provides several options for new drug combinations.
Open Questions
• What other clinically utilised drugs rely on increases in ceramide levels for their efficacy and can they be effectively
partnered with other ceramide inducing agents?
• How does ceramide modulate the Bcl-2 family proteins, Mcl-1 and Bcl-2?
• Are sphingolipid enzyme inhibitors best suited in the frontline or relapsed-refractory setting?
Introduction
Frontline chemotherapeutic regimens for the majority
of haematological malignancies have, until recently,
undergone little change over the last 30 years. The success
of tyrosine-kinase inhibitors (TKI) in chronic myeloid
leukaemia (CML) has significantly increased the 10-year
survival rate to 83%, enabling some patients to cease
therapy (~40%) and achieve long-term remission
(~40% >3 years)1. However, unlike CML which is driven
solely by the BCR-ABL oncogene, most blood cancers are
more genetically heterogeneous displaying complex clonal
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architecture with conventional chemotherapeutic agents
remaining the backbone of most therapy regimens. One
mechanism whereby chemotherapy induces apoptosis in
malignant cells is through increases in the cellular levels
of the pro-apoptotic sphingolipid, ceramide2,3. Sphingo-
lipids are a class of lipids that can exert pleotropic cell
signalling effects. Ceramide is a central component of
sphingolipid metabolism that is tightly regulated due to its
pro-apoptotic effects (Fig. 1). Enzymes involved in the
conversion of ceramide to other sphingolipids have been
implicated in drug resistance by depleting ceramide to
produce pro-survival sphingolipids (Table 1). Indeed,
inhibitors targeting these enzymes have been shown to
induce cell death through inducing the accumulation of
lethal levels of ceramide4–7. Thus, manipulating sphin-
golipid metabolism has shown promise in combination
with conventional chemotherapy, as well as with novel
agents. In this review, we highlight the literature that
examines how targeting sphingolipid metabolism shows
considerable promise for chemo-sensitising patients with
blood cancers.
The sphingolipid cycle
While originally assumed to just play an integral role in
the structure of the cell membrane, sphingolipids have
been found to be prominent players in cell signalling,
capable of exerting a myriad of cell responses. De
novo sphingolipid production commences at the endo-
plasmic reticulum with the condensation of serine and
palmitoyl-CoA by the rate-determining enzyme, serine
palmitoyltransferase to 3-keto-dihydrosphingosine
(Fig. 1)8. Following further modification to dihydro-
sphingosine, ceramide synthases convert dihydro-
sphingosine to dihydroceramide which are then
desaturated to generate ceramides8. From here, these
ceramides can be modified to various sphingolipid species
that modulate membrane composition and signal trans-
duction. For example, ceramides can be glycosylated by
glucosylceramide synthase to glucosylceramides which
can serve as an intermediary for other glycosphingolipids,
phosphorylated by ceramide kinase, modified by the
addition of phosphocholine by sphingomyelinase (SMase)
to form sphingomyelins, or deacylated by ceramidases to
form sphingosine and subsequently, through the action of
sphingosine kinases (SPHKs), generate sphingosine-1-
phosphate (S1P) (Fig. 1)9. Notably, considerable evidence
implicates important roles for several of these sphingoli-
pid metabolic enzymes in tumorigenesis and resistance to
therapy in haematological malignancies (Table 1).
Sphingosine kinases
The “sphingolipid rheostat” is a concept that describes
cell fate as a balance between pro-apoptotic ceramide and
pro-survival S1P9,10. As the SPHKs are critical in the only
exit point for degradation of sphingolipids, via conversion
of sphingosine to S1P, and then its degradation by S1P
lyase, these enzymes represent one of the key players in
maintaining ceramide levels (Fig. 1). Furthermore, S1P
Fig. 1 Overview of the sphingolipid cycle. The pleotropic nature of ceramide allows a promotion of multiple cellular fates including survival,
migration and angiogenesis. Furthermore this also prevents a lethal accumulation of apoptotic sphingolipids (red) such as ceramide by maintaining a
balance of pro-survival lipids (blue). Due to the propensity of transformed cells to deplete ceramide by increasing expression of enzymes, such as
SPHK1/2 and GCS, inhibitors targeting these enzymes have exhibited therapeutic potential by tipping the balance to favour ceramide accumulation
and promote cell death.
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generation by SPHK also directly promotes cell survival as
well as activating oncogenic signalling pathways by acting
as both an intracellular second messenger, and as a ligand
for a family of five S1P-selective G-protein-coupled
receptors11.
Although very similar enzymes, some sequence and
presumed structural diversity between the two human
SPHKs, SPHK1 and SPHK2, is thought to drive partially
different biological functions of these enzymes11. It is
generally accepted that SPHK1 is associated with a pro-
tumorigenic role. Under homeostatic conditions, basal
SPHK1 activity is thought to maintain ceramide levels
in the absence of stimuli to prevent inappropriate
cell death12. Activation of SPHK1 can occur via the
RAS pathway with extracellular signal-regulated kinases
1/2 (ERK1/2) phosphorylating SPHK1 at Serine 22512.
Activated SPHK1 subsequently translocates to the plasma
membrane, via an interaction with calcium and integrin
binding protein 1 (CIB1), to convert sphingosine to
S1P12–14. Due to the frequency with which hyperactiva-
tion of the RAS pathway occurs in cancer, constitutive
phosphorylation and activation of SPHK1 in cancer is
likely to be common, promoting drug resistance by not
only depleting ceramide levels but also promoting pro-
survival signalling9,15,16. Furthermore, drug resistant cell
lines have been shown to also exhibit increased SPHK1
activity and attenuate increases in ceramide which would
otherwise promote apoptosis15–17. Several studies have
shown that targeting SPHK1 can resensitise cells to che-
motherapy, by blocking the conversion of sphingosine to
S1P and generating a bolus of pro-apoptotic ceramide15,
16,18.
Despite catalysing the same reaction, characterising
SPHK2 has proved more elusive with conflicting literature
on its role in tumorigenesis19,20. Nevertheless, targeting
SPHK2 has shown promise in a number of malignancies,
including breast cancer21, acute lymphoblastic leukaemia
(ALL)22 and myeloma5,23.
Ceramidase
Breakdown of ceramide to sphingosine is mediated by
ceramidases, with several homologues described that
function in acidic, neutral, or alkaline pH. The most
characterised form, acid ceramidase (AC) is thought to
localise to acidic compartments, such as lysosomes24. The
degradation of ceramide by AC has highlighted a potential
mechanism for drug resistance by degrading the bolus of
ceramide induced by cancer treatments. Overexpression
of AC has been reported in several solid tumours25 in
addition to acute myeloid leukaemia (AML)4. Pre-clinical
studies utilising AC inhibitors have shown efficacy in
resensitising cells to chemotherapeutics26,27. Although no
direct AC inhibitors are currently under investigation in
clinical trials, interestingly, the clinically available oes-
trogen receptor antagonist, Tamoxifen has demonstrated
AC inhibition, warranting potential investigation as an
adjuvant for chemotherapy regimens28.
Glucosylceramide synthase
Glucosylceramide synthesis is the first step in the gen-
eration of complex glycosphingolipids (Fig. 1). Much of
the interest in glucosylceramide has focussed on its role as
a “sink” for ceramide, with the action of glucosylceramide
synthase (GCS) shunting ceramide through glucosylcer-
amide and the glycosphingolipid pathway. It is no surprise
that the removal of ceramide through this pathway
has been proposed as a mechanism of drug resistance
and multiple studies have identified GCS as a therapeutic
target by preventing the accumulation of lethal levels
of ceramide29–32. The approval of the GCS inhibitor,
Table 1 Role of sphingolipid enzymes in haematological
malignancies
Enzyme Malignancy Role
Acid ceramidase AML Increased expression in patient samples.




AML Suppressed by FLT3 signalling. Mediates
cytotoxicity of FLT3 inhibitors by
induction of lethal mitophagy39
Glucosylceramide
synthase
AML Overexpressed in chemotherapy
resistance cell lines29,30
CLL Upregulated in response to B-cell
receptor stimulation68
Lymphoma Potential role in tumour initiation98
Myeloma Potential role in tumour initiation98
Sphingosine
kinase 1
AML Overexpressed in patient samples.
Increases drug resistance to
chemotherapy and ceramide inducing
strategies16,18
ALL Overexpressed in patient samples78
CML Overexpressed in Imatinib-resistant cell
lines15. Upregulates Mcl-1 in a BCR-ABL




ALL Promotes B-ALL disease progression.
Inhibits histone deacetylases to promote
Myc expression22
Myeloma Upregulated in cell lines and patient
samples5,23
AML acute myeloid leukaemia, B-ALL B cell acute lymphoblastic leukaemia, BCR-
ABL Breakpoint cluster region–Abelson murine leukaemia viral oncogene
homolog 1, CLL chronic lymphocytic leukaemia, FLT3 FMS-like tyrosine kinase
3, PP2A protein phosphatase 2A
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Eliglustat, for clinical use in the lysosomal storage dis-
order, Gaucher’s disease, suggests that GCS inhibition is
well tolerated in humans33 and could provide a means to
investigate combinational studies of GCS inhibition with
chemotherapeutics and targeted agents.
Ceramide synthase
In mammals, six different ceramide synthases (CerS1-6)
have been recognized, each capable of generating varying
ceramide species of differing fatty acyl chain lengths in
both the de novo sphingolipid pathway as well as the
conversion of sphingosine to ceramides in the so-called
sphingolipid salvage pathway (Fig. 1)34. Several studies
have demonstrated that CerS activity is crucial to the
cancer cell killing efficacy of chemotherapeutics35,
tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis36, radiation37 and kinase
inhibitors38,39. Although activation of CerS presents an
attractive therapeutic target, CerS regulation remains
poorly understood40.
Cellular ceramides are increased by chemotherapy
Chemotherapy frequently promotes the accumulation
of ceramide, which appears to contribute to induction of
cancer cell death41–43. While the mechanisms responsible
for this induction of ceramide depends on the che-
motherapy employed, numerous studies have observed
chemotherapy-induced activation of CerS and acid
SMase, as well as inhibition of AC41–44. Notably, among
the genes activated by p53 in response to chemotherapy,
CerS537, CerS645 and neutral SMase46 are prominent.
There is also evidence to suggest that the cysteine pro-
tease, Cathepsin B can degrade SK1 following p53 upre-
gulation by genotoxic stress, increasing ceramide levels47.
Thus, with the widespread effect of chemotherapy
and p53 on manipulating sphingolipid metabolism, direct
modulation of sphingolipid enzymes in combination
with current agents may provide improved clinical
outcomes.
Mechanisms of ceramide-induced cell death
Ceramide exerts its tumour suppressive activities
through multiple mechanisms, including activation of
protein phosphatases 1 (PP1) and 2A (PP2A)48, and
suppression of oncogenes such as Akt49, c-Myc50 and
Bcr–Abl51. Perturbation of sphingolipid homeostasis and
ceramide accumulation within cell membranes has
also been reported to invoke pro-apoptotic signalling
through activation of the unfolded protein response52,
autophagy52 and mitophagy39,53. Furthermore, there is
strong evidence suggesting that ceramide can directly
initiate apoptosis by the formation of channels within the
mitochondrial outer membrane, capable of facilitating
the release of proteins, such as cytochrome c, apoptosis-
inducing factor and second mitochondria-derived acti-
vator of caspases (SMAC)54.
Targeting perturbations in sphingolipid
metabolism in haematological malignancies
Clearly, sphingolipid metabolism is frequently dysre-
gulated in haematological malignancies, and can confer
resistance to many drugs currently employed to treat
these diseases. Thus, there appears potential therapeutic
benefit in combining sphingolipid modulators with clin-
ical chemotherapeutics and novel therapies for the treat-
ment of a range of blood cancers.
Chronic myeloid leukaemia
The BCR-ABL inhibitor Imatinib and subsequent TKIs,
Dasatinib and Nilotinib have dramatically improved sur-
vival rates for CML, with some patients even dis-
continuing treatment due to prolonged molecular
remission status55,56. The emergence of ATP binding site
mutations within BCR-ABL, such as the T315I mutant,
however, confers resistance to most of these ATP-
competitive inhibitors, and presents a key therapeutic
issue57. The recent development of allosteric BCR-ABL
inhibitors, GNF-2 and ABL001 may provide an alternative
option in the future to prevent this58. Analysis of GNF-2
treated cells revealed an increase in ceramide levels sug-
gesting BCR-ABL may suppress ceramide synthesis59.
Augmentation of ceramide levels using the glucosylcer-
amide synthase inhibitor D-threo-l-phenyl-2-decanoyla-
mino-3-morpholino-1-propanol (PDMP), enhanced
apoptosis and resensitised T315I mutant CML cells to
both Imatinib and Nilotinib59 suggesting co-targeting
BCR-ABL with sphingolipid modulating agents may be a
novel strategy to further enhance the efficacy of TKI
treatment.
Comparative analysis of Imatinib sensitive and resistant
K562 CML cells revealed enhanced S1P generation and
reduced ceramide levels as a consequence of SPHK1
upregulation compared to parental Imatinib sensitive
K562 cells15, suggesting a potential role for SPHK1 in
Imatinib resistance. Notably, overexpression of SPHK1
blocked the cytotoxic effects of Imatinib in sensitive K562
cells recapitulating the phenotype of Imatinib resistance15.
Findings by Li et al. corroborated this relationship with
BCR-ABL upregulating SPHK1 activity through MAPK,
PI3K and JAK2 signalling suggesting a positive feedback
loop60. Genetic and chemical targeting of SPHK1 also
uncovered a positive relationship between SPHK1 and
anti-apoptotic protein Mcl-1, whereby overexpression of
SPHK1 increased Mcl-1 levels in a BCR-ABL dependent
manner60.
The precise mechanism between SPHK1 and BCR-
ABL stability was later uncovered with S1P receptor 2
(S1P2) supressing PP2A-mediated de-phosphorylation
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and subsequent degradation of BCR-ABL51. Targeting
S1P/S1P2 signalling resensitised Imatinib-resistant K562
cells and T315I patient blasts to BCR-ABL inhibition51.
Notably, elevated SPHK1 and S1P2 mRNA levels were
found in T315I patient blasts used in this study which
raises the question as to whether there is a correlation
between these genes and BCR-ABL mutational status51.
BCR-ABL inhibitors, Dasatinib, Nilotinib and GFN-2
have also been shown to induce transcription of various
CerS genes to upregulate ceramide production59,61,62.
Intriguingly, Dasatinib treatment was associated with
increases in CerS2,5,6 whereas Nilotinib was associated
with increases in Cers5 expression61,62. Combining either
Dasatinib or Nilotinib with the GCS inhibitor, PDMP,
augmented apoptosis, presumably through synergistic
increases in ceramide levels61. The interplay between
BCR-ABL, SPHK1 and CerS highlights the oncogenic
potential of BCR-ABL in skewing sphingolipid metabo-
lism to favour a pro-survival phenotype, and highlights a
potential therapeutic benefit for combining ceramide
inducers with BCR-ABL inhibitors.
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is an indolent
form of leukaemia with some patients not requiring
treatment in their lifetime63. CLL patients with unfa-
vourable genetic factors such as 17p deletion (del(17p))
however respond poorly to frontline therapy in part due
to the absence of p5364. The addition of the Bcl-2 inhi-
bitor, Venetoclax has been a paradigm shift for p53 null
CLL patients with 79% of relapsed/refractory patients in a
phase II clinical trial responding, 20% of whom exhibited
undetectable disease by flow cytometry65. As always,
resistance to drugs remains a problem with other Bcl-2
family members such as Mcl-1, identified as a marker of
resistance to Venetoclax66. Although still effective in CLL
patients, identifying other drugs to use alongside Vene-
toclax and prevent the emergence of resistance is crucial.
In the context of sphingolipid metabolism, the Bcl-2/
Bcl-xl inhibitor Navitoclax was found to enhance CerS
activity and increase C16 ceramide synthesis. Although,
the mechanism remains to be confirmed, the authors to
proposed that Bcl-2 inhibition allows Bak to interact with
CerS5 or 6 resulting in the production of C16 ceramide67.
Furthermore, combining Navitoclax with either the GCS
inhibitor, PDMP, or the SPHK inhibitor, SKI-II-induced
synergistic increases in ceramide and cell death7.
Interestingly, B-cell receptor (BCR) signalling in pri-
mary CLL cells has been shown to induce glucosylcer-
amide generation, potentially blunting the efficacy of
Rituximab treatment68. Schwamb et al. proposed that
BCR signalling stimulates GCS transcription upon IgM
treatment of primary CLL cells in a manner dependent on
phosphoinositide 3-kinase (PI3K)δ and Bruton’s tyrosine
kinase (BTK) activity68. Notably, treatment of CLL cells
with the PI3Kδ inhibitor, Idelalisib or BTK inhibitor,
Ibrutinib which are currently FDA approved for CLL69,
abrogated increases in GCS transcription and synergised
with the first generation Bcl-2/Bcl-xl inhibitor ABT-
7377,67,68. These data suggest that combining ceramide-
inducing strategies with Bcl-2 inhibitors may exhibit
synergistic activity in CLL.
A recent study by Dielschneider et al. investigating the
use of “lysosomal penetrating” or lysosomotropic agents
in CLL uncovered an increase in S1P phosphatase 1
(SPP1) and sphingosine in primary CLL patient samples70
compared to normal B cells. Lysomotropic agents accu-
mulate within lysosomes, promoting the release of lyso-
somal contents such as cathepsins and the initiation
of non-apoptotic cell death71. As a natural detergent
and lysomotropic agent, sphingosine has been shown
to induce lysosome destabilisation72 and thus may
explain the susceptibility of CLL cells to lysomotropic
agents70. The addition of either sphingosine or SKI-
II augmented the apoptotic response of the lysosomo-
tropic agent Siramesine, against primary CLL cells70. The
clinical relevance of the above findings by Dielschneider
et al. are intriguing particularly with reports of the anti-
CD20 antibody Obinutuzumab inducing lysosomal per-
meabilisation in B-cell malignancies, highlighting its
potential use in combination with ceramide/sphingosine-
generating agents73.
Acute lymphoblastic leukaemia
There is disparity in treatment outcome for ALL with
cure rates for adults at 30–40% despite paediatric cases
being closer to 90%74. Poor risk subtypes such as Phila-
delphia (Ph)-like and Ph positive ALL are frequently
observed in adults (~50%) and typically respond poorly to
chemotherapy75. The addition of a TKI to standard che-
motherapy for Ph positive patients has improved treat-
ment response and survival rates for many of these
patients with initial studies showing complete haemato-
logical response in ~90% of patients76. Like CML,
relapsed Ph positive ALL patients exhibit similar muta-
tions in BCR-ABL that impart TKI resistance, requiring a
move to second and third generation BCR-ABL inhibitors.
A potential role for the SPHKs in ALL was first high-
lighted using studies with the pan SPHK inhibitor, SKI-II,
in combination with the commonly used chemother-
apeutic Vincristine77. SKI-II treatment induced cell death
in ALL cell lines and primary lymphoblasts. As expected,
inhibition of the SPHKs and the accompanying increase in
ceramide synergised with Vincristine treatment77. How-
ever, combining the SPHK2 inhibitor, ABC294640 with
Doxorubicin or Vincristine elicited only an additive effect
suggesting the synergy observed may be a consequence of
SPHK1 inhibition22.
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A role for SPHK1 in contributing to the development of
BCR-ABL driven ALL has been described. Gene expres-
sion data from two separate patient cohorts revealed a
significant increase in SPHK1 expression in BCR-ABL
positive ALL compared with BCR-ABL negative cases,
highlighting a potential relationship that had previously
been described in CML17,60. Deletion of SPHK1 in BCR-
ABL positive, but not BCR-ABL negative murine ALL
models delayed disease incidence implicating SPHK1 as a
significant player in BCR-ABL driven ALL78. Further-
more, combining SPHK inhibitors, SK1-I, SKI-II or
ABC294640 with Imatinib also induced synergistic cell
death in BCR-ABL positive cell lines which collectively
warrants further investigation78.
Enhanced SPHK2 protein levels and activity in ALL
patient samples and cell lines when compared with nor-
mal B-cell progenitors has also been reported22. SPHK2
inhibition was associated with reductions in histone
acetylation of the c-Myc promoter representing new evi-
dence for an oncogenic role for SPHK222. Reductions
in c-Myc expression were observed in BCR-ABL
transformed B-ALL cells from SPHK2 knockout mice,
translating into increased overall survival in vivo22. These
pre-clinical studies may provide the impetus to assess
the addition of ABC294640 alongside BCR-ABL inhibitors
in patients with Ph positive ALL.
Acute myeloid leukaemia
Among drugs in the development pipeline for AML,
selective FLT3 inhibitors Crenolanib and ASP2215 have
exhibited impressive single-agent activity (ORR 52%, CRC
41%) in a phase I/II study of relapsed/refractory AML79.
Recently, work by Dany et al. examined the mechanism of
action of FLT3 inhibitors, including Crenolanib, and
observed reductions in C18-ceramide levels in FLT3
positive AML patient blasts39. The authors attributed this
to striking reduction in CerS1 mRNA levels, suggesting an
inverse relationship between FLT3 activity and CerS1
expression. Restoration of CerS1 upon treatment with
FLT3 inhibition resulted in mitophagy-dependent cell
death suggesting repression of ceramide synthesis may be
an important step in AML pathogenesis. Intriguingly, a
mitochondrial targeted ceramide analogue effectively
suppressed FLT3 inhibitor resistant AML patient samples
in vivo39 suggesting the reactivation of mitochondrial
ceramide synthesis downstream of FLT3 signalling may
be beneficial in overriding FLT3 resistance.
Several groups have observed changes in AC in solid
tumours26,27,80, with its role in AML recently described.
Upregulation of AC mRNA and activity was observed in
AML patient samples compared with normal CD34+
bone marrow cells4. Treatment of AML cell lines with the
AC inhibitor LCL-204 was associated with rapid loss of
the pro-survival Bcl-2 family protein, Mcl-1 and caspase
dependent cell death implicating mitochondrial mediated
apoptosis4. Although, LCL-204 appeared to display some
anti-leukaemic activity in patient-derived xenografts
in vivo, the assessment of circulating blasts within the
periphery as opposed to bone marrow makes it difficult to
draw conclusions from these studies. Overexpression of
AC correlated with an increase in Mcl-1 expression and
blunted the cytotoxic effects of Bcl-2/Bcl-XL inhibitor,
ABT-737. Whilst Tan et al. demonstrate that AC inhibi-
tion results in proteasome-mediated degradation of Mcl-
1, the exact mechanism of how AC upregulates
Mcl-1 was not further explored. Thus, the targeting of
Mcl-1 through AC inhibition warrants further investiga-
tion in combination with Bcl-2 inhibitor, Venetoclax.
Chemoresistant AML cells were also susceptible to cell
death induced by AC inhibition which was correlated with
the increase in cellular ceramide levels4. Although pre-
liminary, these findings serve as a basis for further
investigating the potential for AC inhibitors as chemo-
resensitisers in the relapse/refractory setting.
The oestrogen receptor antagonist, Tamoxifen has also
demonstrated potent inhibition (IC50 ~1 μM) of GCS and
has demonstrated anti-leukaemic activity. Work by
Morad et al. utilising short chain ceramides in combina-
tion with Tamoxifen revealed synergistic cell death in
AML cell lines as a consequence of mitochondrial meta-
bolic collapse typified by decreases in ATP levels and
glycolytic flux81. Tamoxifen treatment prevented the
accumulation of glucosylceramide species, in agreeance
with the proposed role of these molecules as a “sink” for
excess cellular ceramide82. Besides the demonstrated
effects on GCS, Tamoxifen has also been reported to
inhibit AC which may contribute to its cytotoxic effects83.
Nethertheless, the off-target inhibition of GCS by
Tamoxifen, presents an interesting therapeutic angle
given its approval for hormone-dependent breast cancer,
potentially allowing fast track approval as adjuvant ther-
apy in combination with chemotherapy.
Confirmation of SPHK1 as a therapeutic target in AML
has been established by several groups using both genetic
knockdown of SPHK1 and chemical SPHK1 inhibitors.
Chemotherapy resistant AML cell lines exhibited a lack of
ceramide generation upon drug treatment suggesting an
involvement of SPHK1 as a mediator of drug resistance16.
Overexpression of SPHK1 in chemo-sensitive AML cell
lines imparted resistance to chemotherapeutics confirming
SPHK1 as a marker of drug resistance in AML16,18. Genetic
and chemical inhibition of SPHK1 in AML cell lines and
primary patient samples induced cell death84 and synergised
with chemotherapeutic agents18. Interestingly, SPHK1
inhibition-induced synergistic cell death with cytarabine in
the refractory leukaemic initiating cell (LIC) population18.
Although these synergistic effects require further in vivo
evaluation, the findings suggest addition of an SPHK1
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inhibitor to a standard chemotherapeutic regimen has the
potential to greatly enhance clinical responses and reduce
relapse rates by targeting the LIC population.
Recently, a link between SPHK1 and Mcl-1 was eluci-
dated by Powell et al. whereby SPHK1 inhibition resulted in
Mcl-1 degradation18. Loss-of-Mcl-1 coincided with induc-
tion of BH3-only proteins, particularly Noxa, a known
inducer of Mcl-1 degradation85. As Mcl-1 is a marker of
resistance to Bcl-2 inhibitor, Venetoclax, this link highlights
a new angle to target Mcl-1 and enhance the efficacy of
Venetoclax which is exhibiting impressive single-agent
activity (ORR 79%) in CLL, a malignancy highly depen-
dent on Bcl-265 but only exhibited modest single-agent
activity in AML (ORR 19%)86. Follow-up trials with Vene-
toclax in combination with chemotherapy and hypo-
methylating agents are currently ongoing with initial reports
showing promising results87,88. Pre-clinical evidence com-
bining SPHK1 and Bcl-2 inhibition showed synergistic cell
death in AML cell lines by targeting both Mcl-1 and Bcl-218.
Although, the exact mechanism is currently unknown, the
work from both Tan et al.4 and Powell et al.18, suggests
ceramide and S1P regulate Mcl-1 degradation.
A link between ceramide and resistance to Bcl-2 tar-
geting strategies has previously been identified in small
cell lung carcinoma which could explain the synergy
between the two drugs89. Gene correlation analysis for
Navitoclax resistance, identified an atypical Bcl-2 protein,
Bcl-rambo, as a direct inhibitor of CerS2 and −689. This
finding supports in vitro studies demonstrating that the
GCS inhibitor, PDMP synergises with Navitoclax sug-
gesting ceramide augments Bcl-2 targeting strategies7.
The ability of sphingolipid modulating agents such as
those directed against AC4 or SPHK118 to reduce Mcl-1
expression, as well as the synergy observed with Bcl-2
inhibitors7,18, provides considerable impetus to further
explore how ceramide modulates Mcl-1 stability.
Targeting of S1P2 in AML has shown to induce loss-of-
Mcl-1 and synergised with Bcl-2 inhibition recapitulating
the observations with SPHK1 inhibition18. A link between
S1P2 and Mcl-1 stability has been largely overlooked in
the context of cancer biology. We speculate that a change
in Mcl-1 phosphorylation may be responsible for loss-of-
Mcl-1 associated with S1P2 inhibition highlighting
potential involvement of PP2A based on findings observed
in CML51. Furthermore, this suggests that the loss-of-
SPHK1 and its effect on Mcl-1 is two-pronged with
reduced S1P/S1P2 signalling and the accumulation of
ceramide due to the lack of sphingosine processing by
SPHK1. Despite the lack of targeted therapies in wide-
spread clinical use, the potentially broad applicability of
inhibitors of sphingolipid metabolism in AML may pro-
vide significant benefit in a malignancy whose treatment
options are reliant on ceramide accumulation for their
efficacy (Fig. 2).
Multiple myeloma
The repertoire of novel therapies to treat multiple
myeloma has markedly increased over the past two dec-
ades. Of these novel therapies, the proteasome inhibitors
(PIs), particularly Bortezomib (Velcade), have resulted in a
marked improvement in overall response and median
survival rates (from 3 to 6–7 years)90. Sustained mono-
clonal immunoglobulin production by myeloma plasma
cells induces endoplasmic reticulum (ER) stress and
activates the unfolded protein response (UPR) which aims
to reduce global protein translation and correct the
Fig. 2 Targeting sphingolipid metabolism in AML. An overview of targeting sphingolipid enzymes (red) in combination with pre-clinical or
clinically utilised drugs (blue) in AML.
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misfolded protein-induced stress placed on the ER91. To
effect this, proteins that cannot be correctly folded are
transported to the 26S proteasome for degradation,
highlighting the relevance of PIs, which block proteasome
activity and commit the myeloma cell to apoptosis due to
the accumulation of misfolded proteins in the ER lumen
and activation of a terminal UPR92.
Unlike other haematological malignancies, SPHK2
appears to be the dominant SPHK isoform in mye-
loma5,23. Both pharmacological inhibition of SPHK2 using
ABC294640 or K145, and genetic interference of SPHK2
have shown effects on myeloma cell proliferation and
viability5,23. In response to ABC294640, a dual dihy-
droceramide desaturase and SPHK2 inhibitor, loss-of-
myeloma cell viability was associated with degradation
of c-Myc and Mcl-1, similar to the phenotype observed
by Wallington-Beddoe et al. in ALL22. The loss-of-Mcl-1,
the crucial Bcl-2 family member in myeloma93, in
response to ABC29460 appears as a consequence of Noxa
upregulation23, just as it has been shown for Bortezo-
mib94, providing evidence for combination therapies. As
expected, the loss-of-Mcl-1 observed with ABC294640
treatment sensitised myeloma cells to Venetoclax95.
Indeed, combination of the SPHK2 inhibitor K145 and
Bortezomib has been shown to result in synergistic anti-
myeloma effects in vitro and in vivo5. These findings are
supported by studies showing that changes in lipid
saturation in the ER membrane, potentially including the
accumulation of sphingolipids, can activate the UPR
sensors, IREα and PERK independent of the accumulation
of ER luminal misfolded proteins52,96. Thus, the basis of
synergy likely arises from each drug activating ER stress
via distinct mechanisms, culminating in terminal UPR
activation and apoptosis (Fig. 3).
Conclusions
It is well known that sphingolipids are key mediators of
cell fate and can rapidly fluctuate in response to drug
Fig. 3 Exploiting sphingolipid synthesis to enhance the efficacy of proteasome inhibitors. Due to the constitutive production of
immunoglobulin by malignant plasma cells, their reliance on the unfolded protein response (UPR) to prevent an accumulation of misfolded proteins
with the endoplasmic reticulum (ER) for survival renders them susceptible to inducers of ER stress. As the site of de novo sphingolipid synthesis,
accumulation of saturated lipids such as ceramide within the ER, induces a lipid dependent UPR, promoting apoptosis.
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treatment. The emerging findings from multiple haema-
tological malignancies implicating rewiring of sphingoli-
pid metabolism from different enzymes in the metabolic
pathway, such as SPHKs, AC and GCS, highlights
multiple therapeutic angles to induce ceramide accumu-
lation. While the majority of drugs targeting these
enzymes remain in pre-clinical development, others such
as the SPHK2 inhibitor, ABC294640 are under investi-
gation in clinical trials for relapsed/refractory multiple
myeloma (NCT02757326). The pre-clinical data suggest
that SPHK2 inhibition may augment the efficacy of
existing drugs such as Bortezomib and Venetoclax for
myeloma5,23,95. The success of ABC294640 may also
accelerate other SPHK inhibitors into clinical trials. Fur-
thermore, the findings that clinically used small molecule
inhibitors of FLT339, BCR-ABL17 and Bcl-267 increase
ceramide levels warrant further investigation. In parti-
cular, the combining of two separate drugs such as the
FLT3 inhibitor, Quizartinib and the Bcl-2 inhibitor
Venetoclax which have demonstrated synergistic cell
death in AML, could be partially attributed to the
increases in ceramide levels that are produced by each
drug39,67,97. Thus this could provide an opportunity for
targeted combinational therapies under the premise of
synergistic increases in ceramide levels. Finally, repur-
posing approved drugs such as Tamoxifen, which has
activity against AC, GCS and SPHK1 could prove bene-
ficial, particularly in the relapsed/refractory setting where
each of these enzymes can potentially confer drug resis-
tance. Given many of the drugs used in the clinic mod-
ulate ceramide levels, herein provides an opportunity to
partner existing agents with rationally chosen sphingoli-
pid inhibitors to collectively induce lethal levels of cer-
amide that target tumour cells and enhance patient
survival.
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